Also trades as: 0JDI.L (LSE) · $vol 0M
IONS NASDAQ
Ionis Pharmaceuticals, Inc.
1W: -2.2%
1M: -2.4%
3M: -21.5%
YTD: -45.5%
1Y: -39.3%
3Y: -6.7%
5Y: +43.5%
$43.96
+0.54 (+1.24%)
After Hours: $43.72 (-0.24, -0.55%)
Weekly Expected Move ±5.4%
$38
$41
$43
$45
$48
Credit Risk of going bust: higher than 52% of companies Debt: 25.1% of company value Bonds: $115.2M held by 65 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.22B.
Distance to default 4.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.22B.
Distance to default 4.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$874M
Revenue
-7.4% YoY
$-565M
Net Income
-110.6% YoY
$-559M
Free Cash Flow
-91.4% YoY
99.0%
Gross Margin
-38.2%
Op. Margin
-42.8%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-105.4%
ROA-18.9%
ROIC-58.5%
Valuation
P/E-12.7
P/B16.5
EV/EBITDA3.1
Leverage
Debt/Equity5.50
Current Ratio7.88
Interest Cov.-5.6x
Quality Scores
Piotroski F3/9
Altman Z2.36
Beneish M-2.49